Clinical Trials · NCT05029622
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 66
- Start date
- Aug 2021
- Locations
- 14 sites, China
- Primary endpoint
- Percentage of Participants With Luteinising Hormone (LH) Suppression